Results 41 to 50 of about 62,619,193 (270)

Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab

Clinical Kidney Journal, 2023
ABSTRACT We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephrotic syndrome resolved after ...
Stryckers, Marijke, Van Oevelen, Stefaan, Koshy, Priyanka, Sprangers, Ben, Van Craenenbroeck, Amaryllis H.   +4 more
openaire   +4 more sources

Possible role of IL‐23 inhibitor in autoimmune hemolytic anemia

European Journal of Haematology, 2023
AbstractRituximab and prednisone are commonly used treatments for autoimmune hemolytic anemia (AIHA), where the body's immune system attacks and destroys its red blood cells. However, some AIHA patients may become refractory to rituximab treatment, and this can result in continued hemolysis and persistent anemia, making it challenging for affected ...
Naveen Premnath, Urvashi Pandey, Mohak Pandey, K. Venuprasad   +3 more
openaire   +2 more sources

IL-23-mediated ROCK activation promotes Tγδ17 cell migration.

, 2020
(a) IL-7-expanded Tγδ17 cells were stimulated with IL-23 for 6 h in the presence or absence of Y27632 inhibitor or left unstimulated (uns.). Representative histogram shows pSTAT3-Y705 measured by flow cytometry.
Candelas Álvarez-Salamero (8611707), Gloria Pastor-Fernández (8611710), Isabel R. Mariblanca (8611713), Jesús Pino (293477), Raquel Castillo-González (827266), María N. Navarro (8611719), Danay Cibrian (8611716)   +6 more
core   +1 more source

The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans [PDF]

, 2011
IL-23 and Th17 cells are key players in tissue immunosurveillance and are implicated in human immune-mediated diseases. Genome-wide association studies have shown that the IL23R R381Q gene variant protects against psoriasis, Crohn's disease and ...
Di Meglio, P, Chung-Ching Chu, Francesca Capon, Di Meglio, Paola, Napolitano, Luca, Napolitano, L, Ketty Peris, Di Cesare, Antonella, Villanova, Federica, Villanova, F, Richard C. Trembath, Isabella Tosi, Paola Di Meglio, Richard C Trembath, Laggner, Ute, Chu, Chung-Ching, Chu, CC, Capon, Francesca, Federica Villanova, Frank O Nestle, Nestle, FO, Peris, K, Nestle, Frank O., Antonella Di Cesare, Peris, Ketty, Trembath, RC, Laggner, U, Tosi, Isabella, Luca Napolitano, Capon, F, Frank O. Nestle, Ute Laggner, Trembath, Richard C., Di Cesare, A, Tosi, I, Chu Chung-Ching, Peris Ketty, Laggner Ute, Napolitano Luca, Di Meglio Paola, Nestle Frank O., Trembath Richard C., Capon Francesca, Di Cesare Antonella, Villanova Federica, Tosi Isabella   +45 more
core   +2 more sources

How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis

Journal of Dermatological Treatment, 2018
Sir,With the advent of novel biologic agents for psoriasis, such as IL-17 inhibitors and IL-23 inhibitors, the treatment options available for psoriasis have increased considerably.
Mina, Amin, Erica B, Lee, Jashin J, Wu
openaire   +2 more sources

Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis

Annals of Medicine
Background Interleukin (IL)-23 inhibitors—including IL-23p19 inhibitors (guselkumab, mirikizumab, risankizumab) and the IL-12/23p40 inhibitor ustekinumab—are emerging treatments for Crohn’s disease (CD), but comparative data among them remain limited ...
Motoki Kaneko, Atsushi Sakuraba
doaj   +1 more source

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms. [PDF]

Drugs Context
Background: Psoriasis is a chronic inflammatory condition that may develop into psoriatic arthritis (PsA) in a significant number of patients. Clinical signs such as enthesitis and nail involvement have been suggested as early indicators of this ...
Dattola A, Bernardini N, Anedda J, Atzori L, Bonifati C, Bruni PL, Giordano D, Graceffa D, Molinelli E, Moretta G, Mugheddu C, Offidani A, Pagnanelli G, Pallotta S, Papini M, Persechino S, Richetta AG, Tolino E, Trovato F, Pellacani G, Potenza C.   +20 more
europepmc   +2 more sources

Impact of angiotensin converting enzyme inhibition on post- coronary artery bypass interleukin 6 release [PDF]

, 2002
Background: Angiotensin 1 converting enzyme (ACE) inhibitors reduce morbidity and mortality after coronary artery bypass graft surgery (CABG). This benefit may result from an anti- inflammatory action.
Humphries, S.E., Rumley, A., Lowe, G.D., Montgomery, H.E., Sanders, J., Brull, D.J.   +5 more
core   +4 more sources

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis

Frontiers in Pharmacology, 2019
Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease.
Lazaros I. Sakkas, Efterpi Zafiriou, Dimitrios P. Bogdanos   +2 more
doaj   +1 more source

Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis

Pharmaceuticals, 2023
Targeted therapies represent major advancements in the treatment of chronic skin conditions such as psoriasis. While previous studies have shown an increased risk of melanoma and non-melanoma skin cancer (NMSC) in patients receiving TNF-α inhibitors, the
Marta Krzysztofik, Paweł Brzewski, Przemysław Cuber, Artur Kacprzyk, Aleksandra Kulbat, Karolina Richter, Tomasz Wojewoda, Wojciech M. Wysocki   +7 more
doaj   +1 more source